CCL21 as a Potential Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis

Arthritis and Rheumatology - United Kingdom
doi 10.1002/art.40740
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2013English

Screening for Pulmonary Arterial Hypertension in an Unselected Prospective Systemic Sclerosis Cohort

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2017English

Risk Assessment in Patients With Systemic Sclerosis and Pulmonary Arterial Hypertension

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2018English

Haemodynamics and Serial Risk Assessment in Systemic-Sclerosis Associated Pulmonary Arterial Hypertension

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2018English

Right Ventricular Contractility in Systemic Sclerosis-Associated and Idiopathic Pulmonary Arterial Hypertension

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2008English

Pulmonary Hypertension in a Patient With Systemic Sclerosis

IOSR Journal of Dental and Medical Sciences
2017English

Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension

International Journal of Rheumatology
RheumatologyImmunology
2010English

Brain Natriuretic Peptide in Pulmonary Arterial Hypertension: Biomarker and Potential Therapeutic Agent

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2009English

Pulmonary Hypertension in Systemic Sclerosis: Different Phenotypes

European Respiratory Review
PulmonaryRespiratory Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy